The sentiment towards Pfizer has been mixed, with a variety of developments influencing investor opinions. Despite a decrease in short interest by 18.3% and consistent interest from a range of institutional buyers, the stock's performance has been inconsistent. Analysts have questioned if it is too late to buy Pfizer stock, even as the healthcare giant experienced a significant setback from a recent FDA approval seen as negative news for the company. Pfizer's struggle to regain Wall Street's confidence post-Covid and a lackluster market performance have led to its shares trading low. Some experts are looking at this as a buying opportunity, particularly in light of Pfizer's high yield dividend. There is speculation concerning whether Pfizer's stock can rebound to its 2021 highs of $60. Pfizer stock has also seen its share of dramatic fluctuations, ranging from suffering 30% fall in a year to achieving a 'massive' upside and experiencing a record earnings beat. While some believe Pfizer stock is underperforming, others see it as a viable long-term hold or a bargain in S&P 500.
Pfizer Stocks News Analytics from Mon, 13 Nov 2023 08:00:00 GMT to Sun, 30 Jun 2024 16:11:19 GMT - Rating 0 - Innovation -6 - Information 6 - Rumor -4
